Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB018A in moderate-to-severe thyroid eye disease
CTR20232542Phase 2Active
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Sep 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of MHB018A in Graves Orbitopathy (GO), sponsored by Minghui Pharmaceutical, Inc.. Started Sep 2023; status: active.
02
Drugs
MHB018A
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20232542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232542.